Genprex, Inc.
GNPX evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $2.7M
- Lead Asset:
- gpx-002 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for GNPX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GNPX
Genprex, Inc. (GNPX) is a clinical-stage biotechnology company developing gene-therapy product candidates for cancer and diabetes, with lead programs REQORSA in combination with immune checkpoint inhibitors for non-small cell lung cancer and extensive-stage small cell lung cancer.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.7M
Cash Runway
—
Lead Asset
gpx-002 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Genprex, Inc..
Genprex, Inc. (GNPX) is a clinical-stage biotechnology company developing gene-therapy product candidates for cancer and diabetes, with lead programs REQORSA in combination with immune checkpoint inhibitors for non-small cell lung cancer and extensive-stage small cell lung cancer.
- Cash and cash equivalents of $15.2M as of 2026-06-30 [sec].
- Net loss of $4.4M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $14.8M as of 2026-06-30 [sec].
- Phase 2 expansion of REQORSA + Tecentriq in ES-SCLC expected to enroll ~50 patients at 10-15 U.S. sites, with a futility analysis after 25 patients reach 18 weeks of follow-up [sec · filed 2026-07-14].
- Company does not expect product revenue for several years and anticipates needing additional capital to fund operations [sec_mda · as of 2026-05-13].
What works
- REQORSA is being evaluated in combination with approved checkpoint inhibitors (pembrolizumab, atezolizumab) in two Phase 1/2 trials, leveraging established therapies [sec · filed 2026-07-14].
- The company is investigating Trop-2 expression as a potential biomarker to increase likelihood of patient response to REQORSA [sec · filed 2026-05-26].
- Genprex has a diabetes program that aims to directly address beta-cell dysfunction, offering a potentially transformative treatment for Type 2 diabetes [sec · filed 2026-05-14].
What to weigh
- The company has recurring operating losses and reported a net loss of $4.4M for the period ended 2026-06-30 [sec].
- Genprex does not expect to generate product revenue for several years and faces significant uncertainty in obtaining regulatory approval and commercializing candidates [sec_mda · as of 2026-05-13].
- Failure to secure additional funding could force the company to delay, limit, reduce, or terminate R&D programs or commercialization efforts [sec_mda · as of 2026-05-13].
- Cash decreased from $18.0M as of 2026-03-31 to $15.2M as of 2026-06-30, indicating a quarterly cash burn of approximately $2.9M [sec_mda · as of 2026-05-13] [sec].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had $15,154,203 in cash and cash equivalents.”
SEC MD&A · August 14, 2026
Need for additional capital and risk of curtailment
“Failure to receive additional funding could cause us to curtail or cease our operations.”
SEC MD&A · May 13, 2026
No expected product revenue for several years
“We do not expect to generate revenue from product sales unless and until we successfully complete development of, obtain regulatory approval for and begin to commercialize one or more of our current or future product candidates, which we expect will take a number of years and which is subject to significant uncertainty.”
SEC MD&A · May 13, 2026
Catalyst timeline
- 2022-03-30 · Phase 1/2 start of REQORSA + pembrolizumab vs. docetaxel in NSCLC — Initiated a Phase 1/2 open-label, dose-escalation and clinical response study of Quaratusugene Ozeplasmid in combination with pembrolizumab.
- 2024-05-09 · Phase 2 start of REQORSA + atezolizumab maintenance in ES-SCLC — Initiated a Phase 1/2 clinical trial of Quaratusugene Ozeplasmid and atezolizumab maintenance therapy in patients with extensive-stage small cell lung cancer.
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Cash decreased from $18.0M (Mar 2026) to $15.2M (Jun 2026); at current burn rate, runway may be limited without new financing [sec_mda].
- No product revenue expected soon — Company does not expect product sales for several years, creating dependence on external funding [sec_mda · as of 2026-05-13].
- Clinical trial execution risk — Phase 2 expansion of REQORSA + Tecentriq depends on enrollment and positive futility analysis; failure could halt program [sec · filed 2026-07-14].
- Regulatory and commercialization risk — Obtaining regulatory approval and commercializing candidates is subject to significant uncertainty and may take years [sec_mda · as of 2026-05-13].
What to watch
- Enrollment progress and results of the Phase 2 futility analysis for REQORSA + Tecentriq in ES-SCLC, expected after the 25th patient reaches 18 weeks of follow-up [sec · filed 2026-07-14].
- Cash position and any new financing rounds or at-the-market offerings, given the quarterly cash burn and need for additional capital [sec_mda · as of 2026-08-14].
- Updates on the diabetes program and biomarker research (e.g., Trop-2 expression) that could de-risk clinical development [sec · filed 2026-05-26].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run Genprex, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Genprex, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.16
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 10.8%
- Days to cover
- 1.0
- Shares short
- 1,121,624
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GNPX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Genprex, Inc.?
Genprex, Inc. (GNPX) is a clinical-stage biotechnology company developing gene-therapy product candidates for cancer and diabetes, with lead programs REQORSA in combination with immune checkpoint inhibitors for non-small cell lung cancer and extensive-stage small cell lung cancer.
What is Genprex, Inc.'s lead drug candidate?
Genprex, Inc.'s most advanced tracked candidate is gpx-002 (Preclinical) for Type 1 diabetes and Type 2 diabetes.
Who is the CEO of Genprex, Inc.?
Mr. Ryan M. Confer M.S. is the chief executive officer of Genprex, Inc. (GNPX).
Where is Genprex, Inc. headquartered?
Genprex, Inc. (GNPX) is headquartered in Austin, TX, United States.
What therapeutic areas does Genprex, Inc. focus on?
Genprex, Inc. develops therapies across Oncology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.